Candidemia is associated with high mortality rate especially in critically ill (ICU) patients with septic shock and echinocandins such as anidulafungin are recommended as first-line treatment. Available pharmacokinetic studies of anidulafungin in healthy volunteers and in patients with renal or hepatic impairment showed that no dose adjustment is needed even in patients receiving standard intermittent haemodialysis. However, few data are available with continuous veno-venous haemofiltration (CVVH). In this study, the pharmacokinetic of anidulafungin was studied in two ICU patients with candidemia and septic shock undergoing CVVH. Both patients had satisfactory parameters of Cmax (9·04 and 5·68 mg/l, respectively), area under the curve (AUC) (95·18 and 67·48 mg/l h) and Cmin (2·61 and 1·43 mg/l). AUC/MIC ratio and Cmax/MIC values were: 11887 and 8435; 1130·25 and 710, for patients 1 and 2, respectively. Our data confirm that in patients with septic shock anidulafungin presents only mild pharmacokinetic changes compared to data reported during CVVH alone.

Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH

DE ROSA, Francesco Giuseppe;CORCIONE, Silvia;BAIETTO, LORENA;DI PERRI, Giovanni;RANIERI, Vito Marco;D'AVOLIO, ANTONIO
2013

Abstract

Candidemia is associated with high mortality rate especially in critically ill (ICU) patients with septic shock and echinocandins such as anidulafungin are recommended as first-line treatment. Available pharmacokinetic studies of anidulafungin in healthy volunteers and in patients with renal or hepatic impairment showed that no dose adjustment is needed even in patients receiving standard intermittent haemodialysis. However, few data are available with continuous veno-venous haemofiltration (CVVH). In this study, the pharmacokinetic of anidulafungin was studied in two ICU patients with candidemia and septic shock undergoing CVVH. Both patients had satisfactory parameters of Cmax (9·04 and 5·68 mg/l, respectively), area under the curve (AUC) (95·18 and 67·48 mg/l h) and Cmin (2·61 and 1·43 mg/l). AUC/MIC ratio and Cmax/MIC values were: 11887 and 8435; 1130·25 and 710, for patients 1 and 2, respectively. Our data confirm that in patients with septic shock anidulafungin presents only mild pharmacokinetic changes compared to data reported during CVVH alone.
JOURNAL OF CHEMOTHERAPY
25
6
376
378
De Rosa, FG; Corcione, S; Baietto, L; Pasero, D; Di Perri, G; Ranieri, VM; D'Avolio, A
File in questo prodotto:
File Dimensione Formato  
pk anidula cvvh.pdf

embargo fino al 01/01/2015

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 588.97 kB
Formato Adobe PDF
588.97 kB Adobe PDF Visualizza/Apri
Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH.pdf

non disponibili

Tipo di file: PDF EDITORIALE
Dimensione 258.53 kB
Formato Adobe PDF
258.53 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/141696
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact